Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reference-based pricing in Part D

Executive Summary

Beginning Dec. 23, CMS will add a footnote to more places in its Medicare Part D Plan Finder Web site alerting users that reference-based pricing may apply to the cost of certain brands, a spokesman said. Approximately 10 percent of the 2009 Part D contracts use the reference-based pricing, according to the agency. Reference-based pricing in Part D involves the requirement that, on top of a co-pay, members must pay an additional charge if they choose a brand-name drug when its generic equivalent is available 1("The Pink Sheet," Dec. 8, 2008, p. 21). AARP wrote to CMS Dec. 16 requesting changes to Plan Finder to ensure greater transparency on the practice and that beneficiaries who enrolled based on "misleading" information in Plan Finder be permitted to switch plans beyond the Dec. 31 enrollment deadline
Advertisement

Related Content

Reference-Based Pricing In Part D Prompts Transparency Concerns
Reference-Based Pricing In Part D Prompts Transparency Concerns
Advertisement
UsernamePublicRestriction

Register

PS050483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel